Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Kura Oncology Inc
KURA
Healthcare
Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that...
blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:KURA)
New Post
View:
Posts & Comments
Threaded Posts
(89)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 22, 2024 1:15pm
Kura Oncology Receives Breakthrough Therapy Designation for
Just In: $KURA Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML@ Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy
...more
(89)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 30, 2024 11:00am
Kura Oncology stock jumped another 20% on Tuesday: here's wh
BREAKING NEWS: $KURA Kura Oncology stock jumped another 20% on Tuesday: here's why2024-01-30 08:41:38 ET Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive
...more
Viva Gold: Multiple High-Grade Gold Hits Includes 90 Meters at 2.0 gpt Gold
posted May 05, 2024 9:00am by
Viva Gold Corp.
-
|
TG2409 (21.3 meters at 5.1 gpt Au) was drilled as an approximate 40-meter offset to the west of TG2211 (57.9-meters at 5.0 gpt Au commencing at 40 meters depth). TG2408 (18.3 meters at 4.4 gpt Au). TG2407 (89.9 meters@ 2.0 gpt Au). TG2404 (36.6 Meters @ 3.3 gpt Au). “Many geologists go their whole careers without seeing drill results like these ...read more
(0)
•••
Saaaa1
X
View Profile
View Bullboard History
Post by
Saaaa1
on May 06, 2021 8:45pm
$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀
iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver, British Columbia - (Newsfile Corp. - April 20, 2021) - iMining
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Significant New Silver Discoveries in the Famous Keno Hill District in the Yukon
An Opportunity to Join Pulsar Helium on the Ground in Minnesota for a Historic Reservoir Flow Test